Considerable Differences in Burden of Disease at State Level

Share this content:
Considerable Differences in Burden of Disease at State Level
Considerable Differences in Burden of Disease at State Level

TUESDAY, April 10, 2018 (HealthDay News) -- There are considerable differences in the burden of disease at the state level, according to a study published in the April 10 issue of the Journal of the American Medical Association.

Ali H. Mokdad, Ph.D., from the University of Washington in Seattle, and colleagues from the U.S. Burden of Disease Collaborators describe trends in the burden of diseases, injuries, and risk factors at the state level from 1990 to 2016 using the results of the Global Burden of Disease Study.

The researchers observed a decrease in the overall death rates between 1990 and 2016 in the United States, from 745.2 to 578.0 per 100,000 persons. From 1990 to 2016, among adults aged 20 to 55 years, there was a decrease in the probability of death in 31 states and Washington, D.C. The highest and lowest life expectancies at birth were seen for Hawaii (81.3 years) and Mississippi (74.7 years) in 2016. For 1990 and 2016, the leading causes of disability-adjusted life years (DALYs) were ischemic heart disease and lung cancer; the third leading cause was low back pain and chronic obstructive pulmonary disease in 1990 and 2016, respectively. From 1990 to 2016, opioid use disorders moved up from the 11th to the seventh leading cause of DALYs.

"These data can be used to inform national health priorities for research, clinical care, and policy," the authors write.

Abstract/Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »